96 related articles for article (PubMed ID: 19914536)
1. Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?
Oakman C; Pestrin M; Cantisani E; Licitra S; DeStefanis M; Biganzoli L; Di Leo A
Breast; 2009 Oct; 18 Suppl 3():S18-24. PubMed ID: 19914536
[TBL] [Abstract][Full Text] [Related]
2. Predicting anthracycline benefit: have we made any progress?
Moretti E; Oakman C; Di Leo A
Curr Opin Oncol; 2009 Nov; 21(6):507-15. PubMed ID: 19713842
[TBL] [Abstract][Full Text] [Related]
3. Using specific cytotoxics with a targeted mind.
Di Leo A; Claudino WM; Pestrin M; Licitra S; Biganzoli L
Breast; 2007 Dec; 16 Suppl 2():S120-6. PubMed ID: 17720501
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
6. First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment.
Morabito A; Piccirillo MC; Monaco K; Pacilio C; Nuzzo F; Chiodini P; Gallo C; de Matteis A; Perrone F;
Oncologist; 2007 Nov; 12(11):1288-98. PubMed ID: 18055848
[TBL] [Abstract][Full Text] [Related]
7. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
[TBL] [Abstract][Full Text] [Related]
8. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
Tang SC
Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486
[TBL] [Abstract][Full Text] [Related]
9. [The use of adjuvant chemotherapy in stage II breast cancer in the last 25 years--a brief review].
Sulkes A
Harefuah; 2002 Apr; 141(4):374-8, 408. PubMed ID: 12017895
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy for breast cancer.
Hennessy BT; Pusztai L
Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
[TBL] [Abstract][Full Text] [Related]
11. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
12. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.
Pal SK; Childs BH; Pegram M
Breast Cancer Res Treat; 2010 Jan; 119(1):25-32. PubMed ID: 19795206
[TBL] [Abstract][Full Text] [Related]
13. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
Nagykálnai T
Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?
Di Leo A; Biganzoli L; Claudino W; Licitra S; Pestrin M; Larsimont D
Eur J Cancer; 2008 Dec; 44(18):2791-8. PubMed ID: 18993056
[TBL] [Abstract][Full Text] [Related]
15. Advances in adjuvant therapy for breast cancer.
Slamon DJ; Romond EH; Perez EA;
Clin Adv Hematol Oncol; 2006 Mar; 4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. PubMed ID: 16736568
[TBL] [Abstract][Full Text] [Related]
16. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
[TBL] [Abstract][Full Text] [Related]
17. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
[TBL] [Abstract][Full Text] [Related]
19. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.
Estévez LG; Muñoz M; Alvarez I; Fernández Y; García-Mata J; Ruiz-Borrego M; Tusquets I; Seguí MA; Rodríguez-Lescure A; Adrover E; Lluch A
Cancer Treat Rev; 2007 Aug; 33(5):474-83. PubMed ID: 17561350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
